Current Practices in the Management of Chronic Myeloid Leukemia
✍ Scribed by Kantarjian, Hagop M.; Larson, Richard A.; Cortés, Jorge E.; Deering, Kathleen L.; Mauro, Michael J.
- Book ID
- 123421689
- Publisher
- Elsevier
- Year
- 2013
- Tongue
- English
- Weight
- 458 KB
- Volume
- 13
- Category
- Article
- ISSN
- 2152-2650
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase inhibitors (TKIs) at diagnosis in light of recent US Food and Drug Administration approval of nilotinib an
Childhood chronic myelogenous leukemia (CML) is a rare malignancy, and experience with optimal treatment is very limited. Traditionally, allogeneic hematopoietic stem cell transplantation was considered the only curative treatment. Imatinib, a small-molecule inhibitor of the BCR-ABL tyrosine kinase